Abstract blue and purple network particles

Delivering Scalable FSP Solutions for a Top 20 Global Pharmaceutical Company 

1 minute read

Published: June 26th, 2025

When a top 20 global pharmaceutical company issued a competitive RFP seeking support in statistical programming and data management, Phastar was selected as a trusted FSP partner. Since 2020, the partnership has grown significantly, with over 100 Phastar professionals now supporting global clinical research efforts across multiple therapeutic areas.

Case Study Highlights:

  • 30% cost reduction through optimized offshore resourcing
  • 28-day average to fill open roles, with new hires adding value from day one
  • Ongoing collaboration via Executive Steering Committees
  • Scalable support across oncology, rare diseases, vaccines, and more

Entering its sixth year, this partnership reflects the strength and sustainability of Phastar’s FSP models. Our tailored FSP solutions continue to support this global pharmaceutical company in driving operational efficiency and clinical success.

Download the full case study to learn how our flexible, high-performance FSP model is helping global pharma sponsors transform clinical trial delivery.

Related articles

Protecting Trial Integrity- Independent Interim Analysis and IDMC Support in a Phase II Breast Cancer Study

Protecting Trial Integrity- Independent Interim Analysis and IDMC Support in a Phase II Breast Cancer Study

October 29th, 2026 1 minute read

Interim analyses and safety reviews play a critical role in clinical trial oversight, providing decision-makers with ...

Transforming Uncertainty into Statistical Confidence: Simulation-Driven Design for a First-in-Human Reproductive Therapeutic 

Transforming Uncertainty into Statistical Confidence: Simulation-Driven Design for a First-in-Human Reproductive Therapeutic 

July 20th, 2026 1 minute read

Designing a first-in-human study is challenging. Designing one for a novel reproductive therapy with limited prior da...

Turning Complexity into Regulatory Confidence: Designing a Seamless Phase 2b/3 Strategy for FDA Engagement 

Turning Complexity into Regulatory Confidence: Designing a Seamless Phase 2b/3 Strategy for FDA Engagement 

July 20th, 2026 1 minute read

Accelerating clinical development requires more than speed, it demands a careful balance between innovation, scientif...